IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Rebecca M. Henderson sold 8,790 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $241.57, for a total transaction of $2,123,400.30. Following the sale, the director now directly owns 27,486 shares in the company, valued at $6,639,793.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
NASDAQ:IDXX traded up $3.37 during trading hours on Wednesday, hitting $249.55. 344,958 shares of the stock traded hands, compared to its average volume of 515,041. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 14.81. IDEXX Laboratories, Inc. has a fifty-two week low of $176.11 and a fifty-two week high of $256.22. The company has a market cap of $20.88 billion, a P/E ratio of 58.58 and a beta of 0.97.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $1.17 EPS for the quarter, beating the consensus estimate of $1.04 by $0.13. IDEXX Laboratories had a net margin of 17.33% and a return on equity of 354,783.84%. The business had revenue of $576.06 million for the quarter, compared to analysts’ expectations of $575.04 million. During the same period in the previous year, the company posted $1.01 EPS. IDEXX Laboratories’s revenue was up 7.1% on a year-over-year basis. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 4.82 earnings per share for the current year.
Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its holdings in shares of IDEXX Laboratories by 12.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 379,302 shares of the company’s stock valued at $94,697,000 after buying an additional 41,716 shares during the period. Morgan Stanley raised its holdings in shares of IDEXX Laboratories by 15.1% in the 3rd quarter. Morgan Stanley now owns 439,913 shares of the company’s stock valued at $109,830,000 after buying an additional 57,828 shares during the period. Vanguard Group Inc raised its holdings in shares of IDEXX Laboratories by 0.3% in the 3rd quarter. Vanguard Group Inc now owns 8,918,451 shares of the company’s stock valued at $2,226,581,000 after buying an additional 23,970 shares during the period. State of Alaska Department of Revenue raised its holdings in shares of IDEXX Laboratories by 4.0% in the 4th quarter. State of Alaska Department of Revenue now owns 19,228 shares of the company’s stock valued at $3,574,000 after buying an additional 737 shares during the period. Finally, DNB Asset Management AS raised its holdings in shares of IDEXX Laboratories by 9.9% in the 4th quarter. DNB Asset Management AS now owns 18,811 shares of the company’s stock valued at $3,499,000 after buying an additional 1,700 shares during the period. Institutional investors and hedge funds own 87.46% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Rebecca M. Henderson Sells 8,790 Shares of IDEXX Laboratories, Inc. (IDXX) Stock” was first posted by Markets Daily and is the property of of Markets Daily. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.themarketsdaily.com/2019/05/16/rebecca-m-henderson-sells-8790-shares-of-idexx-laboratories-inc-idxx-stock.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Further Reading: No Load Funds
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.